Sugi Predict

Sugi Predict / Targets / LSS

LSS

Lanosterol synthase · P48449 · LSS on Sugi Atlas →

37,521 patent compounds predicted against LSS, 18,327 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL188732 SCHEMBL188732 0.78 11/20
SCHEMBL119016 SCHEMBL119016 0.58 10/20
SCHEMBL538598 SCHEMBL538598 0.65 9/20
SCHEMBL906570 SCHEMBL906570 0.54 9/20
SCHEMBL673338 SCHEMBL673338 0.52 9/20
SCHEMBL673339 SCHEMBL673339 0.52 9/20
SCHEMBL673340 SCHEMBL673340 0.52 9/20
SCHEMBL727892 SCHEMBL727892 0.51 9/20
SCHEMBL119229 SCHEMBL119229 0.46 9/20
SCHEMBL88637 SCHEMBL88637 0.44 8/20
SCHEMBL310618 SCHEMBL310618 0.35 7/20
SCHEMBL890002 SCHEMBL890002 0.36 6/20
SCHEMBL219418 SCHEMBL219418 0.35 5/20
SCHEMBL337078 SCHEMBL337078 0.47 4/20
SCHEMBL109139 SCHEMBL109139 0.36 4/20
SCHEMBL890004 SCHEMBL890004 0.33 4/20
SCHEMBL197287 SCHEMBL197287 0.54 3/20
SCHEMBL159409 SCHEMBL159409 0.54 3/20
SCHEMBL610428 SCHEMBL610428 0.47 3/20
SCHEMBL417043 SCHEMBL417043 0.46 3/20

Clinical trials — most relevant to LSS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
LDL Receptor Under Ezetimibe and Simvastatin PHASE4COMPLETED
Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis PHASE3UNKNOWN
Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia PHASE3COMPLETED
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia PHASE3COMPLETED
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia PHASE3COMPLETED
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia. PHASE3COMPLETED
Efficacy and Safety of Terbinafine and Itraconazole PHASE2/PHASE3UNKNOWN
China Plant Sterol Trial PHASE3COMPLETED
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis PHASE2COMPLETED
Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia PHASE2COMPLETED
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
Simvastatin Therapy in Smith-Lemli-Opitz Syndrome PHASE2COMPLETED
Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome PHASE2COMPLETED
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) PHASE2UNKNOWN
Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease PHASE2COMPLETED
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels PHASE2COMPLETED
SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia PHASE2COMPLETED
The Effect of a Plant Sterols-Enriched Low-Fat Milk on Lipid Profile in Healthy Southern Chinese (COME-PASS) PHASE2COMPLETED
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor PHASE1COMPLETED
The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol nanCOMPLETED
Genetic Study of Sitosterolemia nanCOMPLETED
Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism nanRECRUITING
Study of Smith-Lemli-Opitz Syndrome nanCOMPLETED
Plant Stanols and Gene Expression Profile nanCOMPLETED
A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome nanWITHDRAWN
Epidemiological and Molecular Analysis of Scalp Ringworm in France nanCOMPLETED
Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption nanCOMPLETED
Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LSS binder may also engage these)

ProteinNameSimilarity
P84466 — 0.999 P84466 →
Q8BLN5 — 0.997 Q8BLN5 →
P48450 — 0.993 P48450 →
Q6Z2X6 — 0.988 Q6Z2X6 →
P38605 — 0.985 P38605 →
Q9SLP9 — 0.984 Q9SLP9 →
Q8W3Z3 — 0.982 Q8W3Z3 →
Q6BE24 — 0.979 Q6BE24 →
Q9MB42 — 0.979 Q9MB42 →
Q8W3Z4 — 0.979 Q8W3Z4 →
Q6BE25 — 0.978 Q6BE25 →
A0A125SXN3 — 0.976 A0A125SXN3 →
K7NBZ9 — 0.976 K7NBZ9 →
Q9SXV6 — 0.975 Q9SXV6 →
O82139 — 0.975 O82139 →
A8CDT2 — 0.975 A8CDT2 →
E2IUB0 — 0.974 E2IUB0 →
E2IUA6 — 0.973 E2IUA6 →
E2IUA9 — 0.973 E2IUA9 →
Q8W3Z1 — 0.973 Q8W3Z1 →
A0A0S2IHL6 — 0.973 A0A0S2IHL6 →
O82146 — 0.973 O82146 →
E7DN63 — 0.972 E7DN63 →
O82140 — 0.971 O82140 →
Q2XPU6 — 0.971 Q2XPU6 →
A0A067FI21 — 0.971 A0A067FI21 →
A8C980 — 0.970 A8C980 →
Q9LRH8 — 0.968 Q9LRH8 →
A0AAW1L0L7 — 0.967 A0AAW1L0L7 →
Q4WQ95 — 0.967 Q4WQ95 →